SMS Pharmaceutical plans to foray into CRAMS with investment of  Rs 50 cr for new R&D centre

SMS Pharmaceutical is entering into the contract research and manufacturing services (CRAMS) business by  setting up of a new state-of-the-art global research and development centre at Gagillapur, Medak dist, in Andhra Pradesh at a cost of Rs 50 crore. The company's new R&D centre was recently inaugurated by Dr A Chakravarthy, chairman, National Institute of Pharma Education and Research (NIPER).

The new research facility was constructed in an area of 7.20 acres with 99842 sq ft built up area including pilot scale development plant comprising separate quality assurance block. The company has developed its research centre in a phased manner. For the phase I, it has developed 10 new laboratories at the ground floor of the centre. In the new R&D centre, the company will be developing every year four new molecules with the help of 14 scientists in each unit.

Presently, the company is actively involved in developing new products for the anti-ulcer, hypertensive, cancer, diabetes, anti-fungal and retroviral therapeutic segment. It has around 70 scientists in its old research and development centre and planning to add 170 more scientists by the end of complete expansion in R&D. Till now, the company has filed 7 drugs master files (DMFs) and planning to file 15-16 more DMFs in the next one year's time.